The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation

Blood Transfusion

Volumn 8, Issue 1, 2010, Pages 8-16

  Liumbruno, Giancarlo Maria ^a,b   D'Alessandro, Angelo ^a   Rea, Federica ^c   Piccinini, Vanessa ^a   Catalano, Liviana ^a   Calizzani, Gabriele ^a   Pupella, Simonetta ^a   Grazzini, Giuliano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Ospedale San Giovanni Calibita Fatebenefratelli   (Italy)

^c SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Antenatal immunoprophylaxis; Haemolytic disease of the newborn; Maternal foetal alloimmunisation; Rh(D)

Indexed keywords

RHESUS D ANTIBODY;

ALLOIMMUNIZATION; BLOOD GROUP RHESUS SYSTEM; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG EFFICACY; FETOMATERNAL TRANSFUSION; HUMAN; IMMUNOPROPHYLAXIS; PREGNANCY; PRENATAL CARE; REVIEW; RHESUS INCOMPATIBILITY; RISK REDUCTION; TREATMENT INDICATION;

ERYTHROBLASTOSIS, FETAL; FEMALE; HUMANS; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM;

EID: 74549205826     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2009.0108-09     Document Type: Review

References (81)

1. Bowman J. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43: 1661-6.
2. Dunn PM. Louise Bourgeois (1563-1636): royal midwife of France. Arch Dis Child Fetal Neonatal Ed 2004; 89: F185-7.
3. Bowman J. Rh-immunoglobulin: Rh prophylaxis. Best Pract Res Clin Haematol 2006; 19: 27-34.
4. Bourgeois L. Observations Diverses sur la Sterilité Perte de Fruiot Fecondité Accouchements et Maladies des Femmes et Enfants Nouveaux Naiz. Paris; 1609.
5. Diamond LK, Blackfan KD, Baty JM. Erythroblastosis fetalis and its association with universal edema of the fetus, icterus gravis neonatorum and anemia of the newborn. J Pediatr 1932; 1: 269-309.
6. Darrow RR. Icterus gravis (erythroblastosis neonatorum, examination of etiologic considerations). Arch Pathol 1938; 25: 378-417.
7. Landsteiner K, Wiener AS. An agglutinable factor in human blood recognized by immune sera for Rhesus blood. Proc Soc Exp Biol Med 1940; 43: 223-9.
8. Levine P, Katzin EM, Burnham L. Isoimmunization in pregnancy: its possible bearing on the etiology of erythroblastosis fetalis. JAMA 1941; 116: 825-7.
9. Urbaniak S. The scientific basis of antenatal prophylaxis. Br J Obstet Gynaecol 1998; 105 (Suppl 18): 11-8.
10. Stern K, Goodman HS, Berger M. Experimental isoimmunization to hemo-antigens in man. J Immunol 1961; 97: 1245-57.
11. Clarke CA, Donohoe WTA, McConnell RB, et al. Further experimental studies on the prevention of Rh haemolytic disease. Br Med J 1963; 1: 979-84.
12. Cohen F, Zuelzer WW, Gustafson DC, et al. Mechanisms of isoimmunization. I. The transplacental passage of fetal erythrocytes in homospecific pregnancies. Blood 1964; 23: 621-46.
13. Freda VJ, Gorman JC, Pollack W. Successful prevention of experimental Rh sensitization in man with an anti-Rh gamma2-globulin antibody preparation: a preliminary report. Transfusion 1964; 4: 26-32.
14. Zipursky A, Israels LG. The pathogenesis and prevention of Rh immunization. Can Med Assoc J 1967; 97: 1245-57.
15. Pollack W, Gorman JG, Freda VJ, et al. Results of clinical trials of RhoGAM in women. Transfusion 1968; 8: 151-3.
16. Hartwell EA. Use of Rh immune globulin. Am J Clin Pathol 1998; 110: 281-92.
17. McMaster Conference on Prevention of Rh immunization. 28-30 September, 1977. Vox Sang 1979; 36: 50-64.
18. Scott JR, Beer AE, Guy LR, et al. Pathogenesis of Rh immunization in primigravidas. Fetomaternal versus maternofetal bleeding. Obstet Gynecol 1977; 49: 9-14.
19. Bowman JM, Chown B, Lewis M, Pollock JM. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J 1978; 118: 623-7.
20. Fung Kee Fung K, Eason E, Crane J, et al. Prevention of Rh alloimmunization. J Obstet Gynaecol Can 2003; 25: 765-73.
21. Biffoni F, D'Angiolino A, Massaro AL, et al. Recommendations for the management of haemolytic disease of the newborn. Blood Transfus 2006; 4: 237-50.
22. Bowman JM. The prevention of Rh immunization. Transfus Med Rev 1988; 2: 129-50.
23. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program. Can Med Assoc J 1978; 118: 627-30.
24. Tovey LA, Townley A, Stevenson BJ, Taverner J. The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet 1983; 2: 244-6.
25. Hermann M, Kjellman H, Ljunggren C. Antenatal prophylaxis of Rh immunization with 250 micrograms anti-D immunoglobulin. Acta Obstet Gynecol Scand Suppl 1984; 124: 1-15.
26. Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev 1987; 1: 101-12.
27. Huchet J, Dallemagne S, Huchet C, et al. Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris Region. J Gynecol Obstetr Biol Reprod 1987; 16: 101-11.
28. Trolle B. Prenatal Rh-immune prophylaxis with 300 micrograms immune globulin anti-D in the 28th week of pregnancy. Acta Obstet Gynecol Scand 1989; 68: 45-7.
29. Lee D, Rawlison VI. Multicentre trial of antepartum low-dose anti-D immunoglobulin. Transfus Med 1995; 5: 15-9.
30. Mayne S, Parker JH, Harden TA, et al. Rate of Rh D sensitisation before and after implementation of a community based antenatal prophylaxis programme. BMJ 1997; 315: 1588.
31. Parson ML, Van den Hof MC, Armson BA, et al. A comparison of the rate of Rh(D) alloimmunisation between Nova Scotia and Scotland [abstract]. Br J Obstet Gynaecol 1998; 105 (Suppl 18): 39.
32. MacKenzie IZ, Bowell P, Gregory H, et al. Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. Br J Obstet Gynaecol 1999; 106: 492-7.
33. Jones ML, Wray J, Wight J, et al. A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant. Br J Obstet Gynaecol 2004; 111: 892-902.
34. Bergstrom H, Nilsson LA, Nilsson L, et al. Demonstration of Rh antigens in a 38-day-old fetus. Am J Obstet Gynecol 1967; 99: 130-3.
35. Bowman JM, Pollock J, Penston L. Fetomaternal transplacental hemorrage during pregnancy and after delivery. Vox Sang 1986; 51: 117-21.
36. Chilcott J, Lloyd Jones M, Wight J, et al. A review of the clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for pregnant women who are Rhesus (RhD) negative. National Institute of Clinical Excellence. London; 2002. Available at: http://guidance.nice.org.uk/page.aspx?o=31689.
37. Bowman JM. Preventing Rh sensitisation during pregnancy. Perinatal Care 1978; 2: 24-32.
38. Hensleigh PA. Preventing Rhesus isoimmunization: antepartum Rh immune globulin prophylaxis versus a sensitive test for risk identification. Am J Obstet Gynecol 1983; 146: 749-55.
39. Tabsh KM, Lebherz TB, Crandall BF. Risks of prophylactic anti-D immunoglobulin after second-trimester amniocentesis. Am J Obstet Gynecol 1984; 150: 225-6.
40. Thornton JG, Page C, Foote G, et al. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. BMJ 1989; 298: 1671-3.
41. Contreras M. The prevention of Rh haemolytic disease of the fetus and newborn - general background. Br J Obstet Gynaecol 1998; 105 (Suppl 18): 7-10.
42. Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunization. Cochrane Database Syst Rev 2000; 2: CD000020.
43. Branch DR, Shabani F, Lund N, Denomme GA. Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-â and prostaglandin E2. Transfusion 2006; 46: 1316-22.
44. Kumpel BM. On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 2002; 82: 67-73.
45. Kumpel BM. On the immunological basis of Rh immune globulin (anti-D) prophylaxis [editorial]. Transfusion 2006; 46: 1652-6.
46. MacKenzie IZ, Roseman F, Findlay J, et al. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. BJOG 2006; 113: 97-101.
47. MacKenzie IZ, Bichler J, Mason GC, et al. Efficacy and safety of a new, chromatographically purified Rhesus (D) immunoglobulin. Eur J Obstet Gynecol Reprod Biol 2004; 117: 154-61.
48. Bichler J, Schondorfer G, Pabst G, Andresen I. Pharmacokinetics of anti-D IgG in pregnant RhDnegative women. BJOG 2003; 110: 39-45.
49. Eklund J, Herman M, Kjellman H, Pohja P. Turnover rate of anti-D IgG injected during pregnancy. Br Med J (Clin Res Ed) 1982; 284: 854-5.
50. Controlled trial of various anti-D dosages in suppression of Rh sensitisation following pregnancy. Report to the Medical Research Council by the working party on the use of anti-D immunoglobulin for the prevention of isoimmunization of Rh-negative women during pregnancy. Br Med J 1974; 2: 75-80.
51. ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet 1999; 66: 63-70.
52. U.S. Preventive Services Task Force. Recommendation Statement: Screening for Rh (D) incompatibility. Rockville, MD; 2004. Available at: http://www.ahrq.gov/clinic/3rduspstf/rh/rhrs.pdf.
53. National Institute for Clinical Excellence. Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women. Technology Appraisal No. 41. London; 2002. Available at: http://guidance.nice.org.uk/TA41/ guidance/pdf/English.
54. Parker J, Wray J, Gooch A, et al. British Committee for Standards in Haematology. Guidelines for the use of prophylactic anti-D immunoglobulin. London; 05/12/2006. Available at: http://www.bcshguidelines.com/pdf/Anti-D- 070606.pdf.
55. Lee D, Contreras M, Robson SC, et al. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. Transfus Med 1999; 9: 93-7.
56. National Health and Medical Research Council. Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics. Commonwealth of Australia 2003. Available at: http://www.nba.gov.au/PDF/glines-anti-d.pdf.
57. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Guidelines for the use of Rh (D) immunoglobulin (Anti-D) in obstetrics in Australia. Australia; March 2007. Available at: http://www.ranzcog.edu.au/publications/statements/C-obs6.pdf.
58. Cortey A, Brossard Y. Prevention of fetomaternal Rhesus-D allo-immunization. Practical aspects. J Gynecol Obstet Biol Reprod (Paris) 2006; 35 (Suppl 1): S123-30.
59. Council of Health Insurances. Blood Testing in Pregnancy. Pregnancy Immunization, Hepatitis B and Lues. Kingston, Council of Health Insurances, National Health Inspection; 1998.
60. Muñiz-Diaz E, Oyonarte S, Rodríguez-Villanueva J, et al. Sociedad Española de Transfusión Sanguínea, Sociedad Española de Obstetricia y Ginecología. Protocolo de Diagnóstico y Prevención de la Enfermedad Hemolítica del feto y del Recién Nacido. (Marzo 2008). Available at: h t t p : / / w w w . s e t s . e s /index.php?option=com-content&view=article&id=33: protocolode-diagnostico-y-prevencion-de-la-enfermedad-hemoliticadel-feto-y-del- recien-nacido&catid=43:guias&Itemid=41. Last accessed: 11/12/2009.
61. Hann IM, Gibson BES, Letsky EA. Fetal and Neonatal Haematology. London, Bailliere Tindal; 1991.
62. Choavaratana R, Uer-Areewong S, Makanantakosol S. Fetomaternal transfusion in normal pregnancy and during delivery. J Med Assoc Thai 1997; 80: 96-100.
63. Bowman JM. Controversies in Rh prophylaxis: who needs Rh immune globulin and when should it be given? Am J Obstet Gynecol 1985; 151: 289-94.
64. Chilcott J, Tappendem, Lloyd Jones M, et al. The economics of routine antenatal anti-D prophylaxis for pregnant women who are Rhesus negative. BJOG 2004; 111: 903-7.
65. MacKenzie IZ, Findlay J, Thompson K, Roseman F. Compliance with routine antenatal Rhesus D prophylaxis and the impact on sensitisations: observations over 14 years. BJOG 2006; 113: 839-43.
66. Ben-David G, Sheiner E, Levy A, et al. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients. J Matern Fetal Neonatal Med 2008; 21: 255-9.
67. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007; 21: 101-17.
68. Daniels G, Finning K, Martin P, Summers J. Fetal blood group genotyping: present and future. Ann N Y Acad Sci 2006; 1075: 88-95.
69. Westhoff CM. Molecular testing for transfusion medicine. Curr Opin Hematol 2006; 13: 471-5.
70. Flegel WA. Blood group genotyping in Germany. Transfusion 2007; 47: 47S-53S.
71. Storry JR. New technologies to replace current blood typing reagents. Curr Opin Hematol 2007; 14: 677-81.
72. Hillyer CD, Shaz BH, Winkler AM, Reid M. Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev 2008; 22: 117-32.
73. Avent ND. RHD genotyping from maternal plasma: guidelines and technical challenges. Methods Mol Biol 2008; 444: 185-201.
74. Müller SP, Bartels I, Stein W, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008; 48: 2292-301.
75. Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007; 93: 99-111.
76. Thomson A, Contreras M, Gorick B, et al. Clearance of Rh D-positive red cells with monoclonal anti-D. Lancet 1990; 336: 1147-50.
77. Kumpel BM. Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn. Transfus Clin Biol 1997; 4: 351-6.
78. Kumpel BM. Monoclonal anti-D development programme. Transpl Immunol 2002; 10: 199-204.
79. Béliard R. Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials. Transfus Clin Biol 2006; 13: 58-64.
80. Kumpel BM. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. Clin Exp Immunol 2008; 154: 1-5.
81. Harkness M, Freer Y, Prescott RJ, Warner P. Implementation of NICE recommendation for a policy of routine antenatal anti-D prophylaxis: a survey of UK maternity units. Transfus Med 2008; 18: 292-5.